Phase 0 Radiopharmaceutical–Agent Clinical Development

The evaluation of antibody-targeted or peptide-targeted radiopharmaceuticals as monotherapy or in oncological drug combinations requires programmatic collaboration within the National Cancer Institute (NCI) clinical trial enterprise. Phase 0 trials provide a flexible research platform for the study...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunos, Charles A., Rubinstein, Larry V., Capala, Jacek, McDonald, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461940/
https://www.ncbi.nlm.nih.gov/pubmed/33014772
http://dx.doi.org/10.3389/fonc.2020.01310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461940/
https://www.ncbi.nlm.nih.gov/pubmed/33014772
http://dx.doi.org/10.3389/fonc.2020.01310

Ejemplares similares